Vincent Le Bon, Head of Department CEA-SHFJ

Pr. Vincent Lebon

Director of UMR BioMaps and Head of CEA-SHFJ, Paris-Saclay University

“Thanks to this unique Lemer Pax equipment, the SHFJ is able to produce radiopharmaceuticals for medical research with a high degree of reliability. These radiopharmaceuticals are used to carry out molecular imaging clinical trials at the SHFJ, as well as in around eight French university hospitals, to which we deliver the radiolabelled molecules using the Lemer Pax equipment. These clinical trials provide invaluable insights into the mechanisms of neurological and cancer diseases and into patient response to innovative therapies.”

To learn more, find our case study on the Frédéric Joliot Hospital in Orsay, France here

On the same topic

27 February 2024

Better understanding, prediction and treatment of cancers and neurodegenerative diseases: the example of the Frédéric Joliot Hospital in Orsay

Better understanding, prediction and treatment of cancers and neurodegenerative diseases. This is the main mission of the CEA, Frédéric Joliot Hospital Department (SHFJ), through its pioneering nuclear medicine department and its BioMaps (Multimodal Biomedical Imaging Paris-Saclay), located within the Orsay...

14 November 2023

Nuclear fusion, the example of ITER

ITER (International Thermonuclear Experimental Reactor, also meaning "path" in Latin) is a scientific programme and challenge. Its aim is to carry out controlled nuclear fusion experiments at unprecedented levels of power and duration, and to understand the dynamics involved. Due to its size, the ITER tokamak will be the most powerful tokamak ever built. To achieve this objective, it will be necessary to create neutron-absorbing materials in the mortar family: lightweight and hydrogen-rich.

radiopharmacy hot cells safety reliability

16 February 2023

Lemer Pax in the race to develop radiopharmacy

Radiopharmacy is the set of human and material resources necessary for the exercise of this activity, which uses radioactive sources for the preparation of radiopharmaceutical drugs used in Nuclear Medicine.

BACK